CAMBRIDGE, Mass. — Two Chinese drug makers have already taken advantage of new rules that ease the way for pre-revenue biotechs to raise capital on Hong Kong’s stock exchange: hepatology-focused drug developer Ascletis applied to list there last month, and diabetes drug maker Hua Medicine did the same on Wednesday.

But Hong Kong officials want U.S. drug makers to follow in their footsteps — and so a delegation traveled 8,000 miles to make their case during the BIO conference in Boston. In an event on Wednesday billed as a roadshow, officials from the stock exchange and other regional industry boosters talked up the virtues of doing business in Hong Kong to a room full of executives from U.S. drug makers, along with industry investors and bankers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy